Current joint European Society of Cardiology and European Respiratory Society pulmonary hypertension clinical practice guidelines recommend double oral therapy for intermediate-risk pulmonary arterial hypertension patients . They recommend upfront triple combination therapy for high-risk patients only, but retrospective data suggests triple therapy including parenteral prostacyclins may be better.
The phase IV, multicentre, prospective, randomised, two-arm, open-label TripleTRE trial will be conducted on 110 patients, 24-48 weeks to provide the first prospective evidence to answer this crucial question: should we “hit hard and early” from diagnosis?
Read more at this link on the ERJ Open Research 2026
Citation
Sitbon O, Agoston G, Badagliacca R, Hajnalka Balint O, Blanco I, Coman IM, Ewert R, Halank M, Jansa P, Kopeć G, Kurzyna M, Tenes A, Opitz C, Plácido R, Přeček J, Riou M, Steringer-Mascherbauer R, Țilea I, Lang IM. Safety and efficacy of upfront triple therapy including parenteral treprostinil compared to double oral therapy in PAH (TripleTRE): study protocol for a randomised trial. ERJ Open Res. 2026 Jan 19;12(1):00458-2025. doi: 10.1183/23120541.00458-2025. PMID: 41561104; PMCID: PMC12813682.Copy